Two Cells Co., Ltd.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Culture Medium Additive for Use in Serum-Free Culturing of Animal Cell, Kit and Use Thereof (US 9,074,176) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Cartilage-damage treatment agent and method for producing same (US 10,507,266) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Method for distinguishing mesenchymal stem cell using molecular marker and use thereof (US 9,234,897) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,184,112 | Culture Medium Additive for Use in Serum-Free Culturing of Animal Cell, Kit and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,074,176 | Culture Medium Additive for Use in Serum-Free Culturing of Animal Cell, Kit and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,131,877 | Differentiation-inducing culture medium additive and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,234,897 | Method for distinguishing mesenchymal stem cell using molecular marker and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,394,521 | Cell preparation containing mesenchymal stem cells, and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,507,266 | Cartilage-damage treatment agent and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 12,788,778 | Composition for Treating Central Nervous System Diseases, Method for Producing Composition for Treating Central Nervous System Diseases, and Method for Producing Therapeutic Formulation for Central Nervous System Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 2 patents in force now held by others · 8 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 9 no status recorded